Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer.

Alessandra CavaliereSuxia SunSupum LeeJacob BodnerZiqi LiYiyun HuangSheri L MooresBernadette Marquez-Nostra

Published in: European journal of nuclear medicine and molecular imaging (2020)

We have successfully prepared a radiolabeled bispecific antibody, [89Zr]ZrDFO-amivantamab, and evaluated its pharmacologic and imaging properties in comparison with its single-arm antibodies and non-specific isotype controls. [89Zr]ZrDFO-amivantamab demonstrated the greatest uptake in tumors co-expressing EGFR and c-MET.

Keyphrases

pet imaging
tyrosine kinase
epidermal growth factor receptor
small cell lung cancer
positron emission tomography
high resolution
computed tomography
fluorescence imaging
wild type